We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

December 05, 2024, 04:52 am ET, BY Momei- Contributor, Stock Traders Daily| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

In trading on Monday, shares of Merus NV (Symbol: MRUS) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $44.16 per share. By comparison, the current ...

In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...